Aktiia has raised CHF 6 million from Redalpine, Translink Capital, and others. Verve Ventures contributed more than CHF 1 million to this round. 

Aktiia has developed an optical method of measuring blood pressure at the wrist. It translates input from standard optical sensors into accurate measurements 24/7 around the clock, a large improvement over the usual sporadic method using a cuff. Aktiia plans to license its technology to third parties and is developing an own sensing bracelet. Aktiia is addressing a market of over 1.7 billion adults with hypertension, half of whom aren’t even aware of their condition. Aktiia’s technology is based on over a decade of research at the Swiss Center for Electronics and Microtechnology (CSEM).

With unfalsified around the clock measurements, Aktiia has the potential to radically change blood pressure measurement and address an enormous market with 1 in 3 adults affected by hypertension worldwide”, explains Romeo Bütler, Investment Manager.

The funds raised will allow Aktiia to go to market with the product.

Read our interview with the founders here.